Epo is effective in improving haematological response and RBCT requirements, and appears to have a positive effect on HRQoL. The incidence of side-effects and effects on survival remains highly uncertain. If there is no impact on survival, it seems highly unlikely that epo would be considered a cost-effective use of healthcare resources.